Four Ways to Improve Your Fleet’s Safety Culture

Novavax Gains Over 50% In June: What's Driving The Rally?

Novavax, Inc. (NASDAQ: NVAX) shares have been on a strong run since mid-May, with multiple catalysts driving the stock to stratospheric levels.It's a comeback for the company, which saw its stock plummet in February 2019 in the wake of a failed late-stage trial of its respiratory syncytial virus vaccine candidate ResVax.Novavax's Stock Trajectory: Novavax shares, which were trading mostly at sub-$5 levels since the start of 2020, began to pick up steam in late January when its influenza vaccine candidate NanoFlu was accorded Fast Track Designation.After trading at single-digit levels, the stock made the next leg up in late February after the company published positive pre-clinical data for NanoFlu and an update on its COVID-19 vaccine program.The company said Feb. 26 it is assessing multiple nanoparticle vaccine candidates in animal studies and expects to have an optimal candidate for human testing by the end of spring 2020, helping the stock breach...